Bioventus to Continue Distributing SUPARTZ FX Through 2028

Bioventus, a global developer of orthobiologic solutions, has entered into an extension of its agreement with Seikagaku Corporation to continue distributing SUPARTZ FX, a five-injection, hyaluronic acid (HA) product used for joint lubrication in the treatment of pain associated with knee osteoarthritis (OA). Under terms of this new agreement, Bioventus will be the exclusive distributor of SUPARTZ FX in the United States through May 2028.
 
“We are pleased SUPARTZ FX will remain in the Bioventus portfolio, along with three-injection HA GELSYN-3 and DUROLANE, our single-injection HA, for many years to come,” said Tony Bihl, CEO of Bioventus. “Joint fluid treatments safely manage knee osteoarthritis pain allowing people to resume active lives and we believe our complement of HA offerings is unmatched in meeting the varied needs of patients, physicians and payers in the U.S. This is consistent with our strategy to be a market leading biologics company in treatments for OA.”
 
Durham, N.C.-based Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Orthobiologic products from Bioventus include offerings for bone healing, bone graft and knee osteoarthritis. Its EXOGEN Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSI, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1 percent.